Salarius Pharmaceuticals, Inc. financial data

Symbol
SLRX on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 157% % 382%
Return On Equity -401% % -186%
Return On Assets -156% % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,862,178 shares 307%
Common Stock, Shares, Outstanding 944,491 shares -34%
Entity Public Float $1,500,431 USD -70%
Common Stock, Value, Issued $94 USD -35%
Weighted Average Number of Shares Outstanding, Basic 481,587 shares 464%
Weighted Average Number of Shares Outstanding, Diluted 481,587 shares 464%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $429,085 USD -34%
General and Administrative Expense $4,639,018 USD 1.7%
Operating Income (Loss) $5,068,103 USD 2.8%
Net Income (Loss) Attributable to Parent $5,004,758 USD -0.22%
Earnings Per Share, Basic 7 USD/shares 84%
Earnings Per Share, Diluted 7 USD/shares 84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,809,680 USD 46%
Other Assets, Current $80,949 USD -32%
Assets, Current $6,064,938 USD 59%
Other Assets, Noncurrent $32,094 USD -12%
Assets $6,097,032 USD 58%
Accounts Payable, Current $1,104,184 USD 566%
Liabilities $1,848,967 USD 98%
Retained Earnings (Accumulated Deficit) $85,464,443 USD -6.2%
Stockholders' Equity Attributable to Parent $4,248,065 USD 45%
Liabilities and Equity $6,097,032 USD 58%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,181,714 USD 13%
Net Cash Provided by (Used in) Financing Activities $545,566 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 944,491 shares -34%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $636,148 USD 58%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,809,680 USD 46%
Interest Paid, Excluding Capitalized Interest, Operating Activities $4,094 USD 1.9%
Deferred Tax Assets, Valuation Allowance $17,098,218 USD 7.5%
Deferred Tax Assets, Gross $17,098,218 USD 7.5%
Deferred Tax Assets, Operating Loss Carryforwards $8,349,314 USD 35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $89,712,414 USD 7.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $1,106 USD -0.09%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%